indexado en
  • Base de datos de revistas académicas
  • Abrir puerta J
  • Genamics JournalSeek
  • Claves Académicas
  • DiarioTOCs
  • Infraestructura Nacional de Conocimiento de China (CNKI)
  • Directorio de publicaciones periódicas de Ulrich
  • Biblioteca de revistas electrónicas
  • Búsqueda de referencia
  • Universidad Hamdard
  • EBSCO AZ
  • OCLC-WorldCat
  • Catálogo en línea SWB
  • Biblioteca Virtual de Biología (vifabio)
  • Publón
  • Fundación de Ginebra para la Educación e Investigación Médica
  • pub europeo
  • Google Académico
Comparte esta página
Folleto de diario
Flyer image

Abstracto

Cutaneous Adverse Reactions to Imatinib: A Case Report of a Successful Slow Protocol for Induction of Drug Tolerance

Camilla Di Paolo, Stefano Minetti, Michela Mineni, Silvia Inverardi, Fabio Lodi Rizzini, Massimo Cinquini and Cinzia Tosoni

Imatinib mesylate (Gleevec®- Novartis, UK) is a selective tyrosine kinase inhibitor widely used for the treatment of hematologic diseases such as chronic myeloid leukemia (CML). Administration of Imatinib has been related to both cutaneous side effects and hypersensitivity reactions. Since it often is a unique therapeutic option for the treatment of CML, desensitization becomes an option in patients who develop hypersensitivity reactions and do not have equally effective therapeutic options. We hereby propose a possible slow protocol for induction of tolerance, suitable for patients who develop cutaneous delayed reactions.